Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Rating) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 130,200 shares, an increase of 45.0% from the December 31st total of 89,800 shares. Based on an average daily volume of 101,000 shares, the short-interest ratio is currently 1.3 days.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Hedge funds and other institutional investors have recently modified their holdings of the business. Simplex Trading LLC boosted its stake in shares of Global X Genomics & Biotechnology ETF by 198.6% during the third quarter. Simplex Trading LLC now owns 2,311 shares of the company's stock valued at $29,000 after purchasing an additional 1,537 shares in the last quarter. FORVIS Wealth Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the third quarter valued at approximately $150,000. Avidian Wealth Solutions LLC boosted its stake in Global X Genomics & Biotechnology ETF by 6.8% in the second quarter. Avidian Wealth Solutions LLC now owns 12,302 shares of the company's stock valued at $150,000 after acquiring an additional 788 shares in the last quarter. Stelac Advisory Services LLC boosted its stake in Global X Genomics & Biotechnology ETF by 71.2% in the second quarter. Stelac Advisory Services LLC now owns 12,742 shares of the company's stock valued at $156,000 after acquiring an additional 5,301 shares in the last quarter. Finally, Beaumont Financial Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter valued at approximately $166,000.

Global X Genomics & Biotechnology ETF Price Performance

Shares of NASDAQ GNOM traded up $0.12 during midday trading on Friday, reaching $13.83. 64,314 shares of the company's stock traded hands, compared to its average volume of 69,001. The stock's 50 day simple moving average is $13.08 and its 200-day simple moving average is $13.45. Global X Genomics & Biotechnology ETF has a one year low of $10.48 and a one year high of $17.02.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.

See Also

• Get a free copy of the StockNews.com research report on Global X Genomics & Biotechnology ETF (GNOM)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.